Patrick Owens, MD
Otolaryngology · Birmingham, ALNPI 1790028199
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,625 of the $26,183 with a category attached, or 71.1%. AbbVie accounts for 73.5% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $21,703, more than ten times the $867 reported in 2019. Among otolaryngology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 249 payments — averaging $105.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$19K
- Pfizer$2K
- Inspire Medical Systems, Inc.$1K
- Intersect ENT, Inc.$721
- Regeneron Healthcare Solutions, Inc.$583
- Optinose US, Inc.$460
- plus $2K from 24 others
What the payments were for
- Consulting fees$1,5256%
- Speaking & faculty fees$18,62571%
- Food & beverage$5,99923%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $19,238 |
| Pfizer | 28 | $1,937 |
| Inspire Medical Systems, Inc. | 28 | $1,164 |
| Intersect ENT, Inc. | 21 | $721 |
| Regeneron Healthcare Solutions, Inc. | 29 | $583 |
| Optinose US, Inc. | 33 | $460 |
| Stryker | 13 | $373 |
| GSK | 14 | $328 |
| Medtronic | 9 | $295 |
| Sanofi | 8 | $253 |
| Integra Lifesciences Corporation | 4 | $146 |
| Merz Pharmaceuticals, LLC | 1 | $110 |
| Aroa Biosurgery Incorporated | 2 | $84 |
| Olympus America Inc. | 3 | $62 |
| Aerin Medical Inc. | 2 | $56 |
| Amgen | 2 | $53 |
| Neurent Medical Limited | 1 | $39 |
| Johnson & Johnson | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| AstraZeneca | 1 | $25 |
| Globus Medical | 1 | $23 |
| Acclarent, Inc | 1 | $21 |
| Baudax Bio Inc. | 1 | $19 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $18 |
| Covidien LP | 1 | $18 |
| KARL Storz Endoscopy-america | 1 | $17 |
| Merck | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Cochlear Americas | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$15,125
- QULIPTA$8,750
- NURTEC ODT$1,525
- Inspire Upper Airway Stimulation System$817
- PROPEL$258
- CLARIFIX$126
- XEOMIN$110
How this compares
$26,183 in reported general payments places this provider in the 95th percentile of 155 otolaryngology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 16 | $21,850 |
| Famotidine | 395 | $6,707 |
| Ipratropium Bromide | 167 | $6,295 |
| Azelastine Hcl | 164 | $5,328 |
| Fluticasone Propionate | 250 | $4,095 |
| Epinephrine | 11 | $3,022 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 16 | $1,776 |
| Nortriptyline Hcl | 98 | $1,523 |
| Montelukast Sodium | 73 | $1,281 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 17 | $1,208 |
| Pantoprazole Sodium | 89 | $942 |
| Mometasone Furoate | 32 | $663 |
| Cefdinir | 28 | $660 |
| Omeprazole | 34 | $648 |
| Methylprednisolone | 70 | $579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $1,937 | $21,85016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 155 otolaryngology providers in Alabama.
Other otolaryngology in Birmingham
- Michael SillersBirmingham$53K
- Justin TurnerBirmingham$34K
- Bradford WoodworthBirmingham$27K
- Kirk WithrowBirmingham$22K
- Do-Yeon ChoBirmingham$19K
- Andrew FusonBirmingham$18K
- Benjamin GreeneBirmingham$15K
- William BarberBirmingham$13K
- Dennis PappasBirmingham$13K
- Ryan MarshallBirmingham$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.